A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology

Neuropharmacology

Volumn 51, Issue 6, 2006, Pages 1086-1098

  Dickson, Louise ^a   Aramori, Ichiro ^b   McCulloch, James ^a   Sharkey, John ^a   Finlayson, Keith ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Ca2+ i; cAMP i; hVPAC PAC receptors; Maxadilan M65; PG97 269 PG99 465; VIP PACAP

Indexed keywords

ALANINE; CALCIUM; CYCLIC AMP; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; M 65; MAXADILAN; PD 97 269; PG 97 269; PG 99 465; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CALCIUM SIGNALING; CELL CULTURE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; CALCIUM SIGNALING; CELL LINE, TUMOR; CELLS, CULTURED; CHO CELLS; CRICETINAE; CYCLIC AMP; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; TRANSFECTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 33751082695     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.07.017     Document Type: Article

References (53)

1. Akesson L., Ahren B., Edgren G., and Degerman E. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Endocrinology 146 (2005) 744-750
2. Aramori I., and Nakanishi S. Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells. Journal of Biological Chemistry 267 (1992) 12468-12474
3. Ciccarelli E., Vilardaga J.P., De Neef P., Di Paolo E., Waelbroeck M., Bollen A., and Robberecht P. Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Regulatory Peptides 54 (1994) 397-407
4. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and the effects of mutating receptors. British Journal of Pharmacology 125 (1998) 924-947
5. Colquhoun D. The quantitative analysis of drug-receptor interactions: a short history. Trends in Pharmacological Sciences 27 (2006) 149-157
6. DeHaven W.I., and Cuevas J. VPAC receptor modulation of neuroexcitability in intracardiac neurons: dependence on intracellular calcium mobilization and synergistic enhancement by PAC1 receptor activation. Journal of Biological Chemistry 279 (2004) 40609-40621
7. Delgado M., Abad C., Martinez C., Juarranz M.G., Leceta J., Ganea D., and Gomariz R.P. PACAP in immunity and inflammation. Annals of the New York Academy of Sciences 992 (2003) 141-157
8. Delgado M., Pozo D., and Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacological Reviews 56 (2004) 249-290
9. i and inositol phosphates in human neuroblastoma NB-OK-1 cells. Peptides 14 (1993) 1111-1118
10. Delporte C., Poloczek P., De Neef P., Vertongen P., Ciccarelli E., Svoboda M., Herchuelz A., Winand J., and Robberecht P. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor. Molecular and Cellular Endocrinology 107 (1995) 71-76
11. Deutsch P.J., and Sun Y. The 38-amino acid form of pituitary adenylate cyclase-activating polypeptide stimulates dual signaling cascades in PC12 cells and promotes neurite outgrowth. Journal of Biological Chemistry 267 (1992) 5108-5113
12. Dickinson T., and Fleetwood-Walker S.M. VIP and PACAP: very important in pain?. Trends in Pharmacological Sciences 20 (1999) 324-329
13. Eggenberger M., Born W., Zimmermann U., Lerner E.A., Fischer J.A., and Muff R. Maxadilan interacts with receptors for pituitary adenylyl cyclase activating peptide in human SH-SY5Y and SK-N-MC neuroblastoma cells. Neuropeptides 33 (1999) 107-114
14. + channel?. European Journal of Pharmacology 412 (2001) 203-212
15. Gomariz R.P., Martinez C., Abad C., Leceta J., and Delgado M. Immunology of VIP: a review and therapeutical perspectives. Current Pharmaceutical Design 7 (2001) 89-111
16. Gourlet P., De Neef P., Cnudde J., Waelbroeck M., and Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18 (1997) 1555-1560
17. Harmar A.J. Family-B G-protein-coupled receptors. Genome Biology 2 (2001) 3013.1-3013.10
18. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., and Waschek J.A. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacological Reviews 50 (1998) 265-270
19. Harmar A.J., Marston H.M., Shen S., Spratt C., West K.M., Sheward W.J., Morrison C.F., Dorin J.R., Piggins H.D., Reubi J.C., Kelly J.S., Maywood E.S., and Hastings M.H. The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 109 (2002) 497-508
20. Itri J., and Colwell C.S. Regulation of inhibitory synaptic transmission by vasoactive intestinal peptide (VIP) in the mouse suprachiasmatic nucleus. Journal of Neurophysiology 90 (2003) 1589-1597
21. Laburthe M., and Couvineau A. Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regulatory Peptides 108 (2002) 165-173
22. i increase but not adenylate cyclase stimulation. Cellular Signalling 17 (2005) 17-24
23. i and cyclic AMP in CHO cells expressing Galpha16. Cell Calcium 30 (2001) 229-234
24. Langer I., Vertongen P., Perret J., Cnudde J., Gregoire F., De Neef P., Robberecht P., and Waelbroeck M. VPAC(1) receptors have different agonist efficacy profiles on membrane and intact cells. Cellular Signalling 14 (2002) 689-694
25. Langer I., Vertongen P., Perret J., Waelbroeck M., and Robberecht P. A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector. Molecular Endocrinology 16 (2002) 1089-1096
26. Langlet C., Gaspard N., Nachtergael I., Robberecht P., and Langer I. Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells. Peptides 25 (2004) 2079-2086
27. Lutz E.M., Ronaldson E., Shaw P., Johnson M.S., Holland P.J., and Mitchell R. Characterization of novel splice variants of the PAC(1) receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP. Molecular and Cellular Neuroscience 31 (2005) 193-209
28. MacKenzie C.J., Lutz E.M., McCulloch D.A., Mitchell R., and Harmar A.J. Phospholipase C activation by VIP1 and VIP2 receptors expressed in COS 7 cells involves a pertussis toxin-sensitive mechanism. Annals of the New York Academy of Sciences 805 (1996) 579-584
29. MacKenzie C.J., Lutz E.M., Johnson M.S., Robertson D.N., Holland P.J., and Mitchell R. Mechanisms of phospholipase C activation by the vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide type 2 receptor. Endocrinology 142 (2001) 1209-1217
30. McCulloch D.A., Lutz E.M., Johnson M.S., MacKenzie C.J., and Mitchell R. Differential activation of phospholipase D by VPAC and PAC1 receptors. Annals of the New York Academy of Sciences 921 (2000) 175-185
31. McCulloch D.A., Lutz E.M., Johnson M.S., Robertson D.N., MacKenzie C.J., Holland P.J., and Mitchell R. ADP-ribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC(1) receptor splice variant. Molecular Pharmacology 59 (2001) 1523-1532
32. McCulloch J., and Edvinsson L. Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide. American Journal of Physiology 238 (1980) H449-H456
33. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., Culler M.D., and Coy D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochemical and Biophysical Research Communications 164 (1989) 567-574
34. Miyata A., Jiang L., Dahl R.D., Kitada C., Kubo K., Fujino M., Minamino N., and Arimura A. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochemical and Biophysical Research Communications 170 (1990) 643-648
35. Moreno D., Gourlet P., De Neef P., Cnudde J., Waelbroeck M., and Robberecht P. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor. Peptides 21 (2000) 1543-1549
36. Moro O., and Lerner E.A. Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. Journal of Biological Chemistry 272 (1997) 966-970
37. Moro O., Wakita K., Ohnuma M., Denda S., Lerner E.A., and Tajima M. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist. Journal of Biological Chemistry 274 (1999) 23103-23110
38. Nicole P., Lins L., Rouyer-Fessard C., Drouot C., Fulcrand P., Thomas A., Couvineau A., Martinez J., Brasseur R., and Laburthe M. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. Journal of Biological Chemistry 275 (2000) 24003-24012
39. Piggins H.D., and Cutler D.J. The roles of vasoactive intestinal polypeptide in the mammalian circadian clock. Journal of Endocrinology 177 (2003) 7-15
40. Pisegna J.R., and Wank S.A. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. Journal of Biological Chemistry 271 (1996) 17267-17274
41. Pozo D., and Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?. FASEB Journal 18 (2004) 1325-1334
42. Said S.I., and Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 169 (1970) 1217-1218
43. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., and Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365 (1993) 170-175
44. Sreedharan S.P., Patel D.R., Xia M., Ichikawa S., and Goetzl E.J. Human vasoactive intestinal peptide 1 receptors expressed by stable transfectants couple to two distinct signaling pathways. Biochemical and Biophysical Research Communications 203 (1994) 141-148
45. Uchida D., Tatsuno I., Tanaka T., Hirai A., Saito Y., Moro O., and Tajima M. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor. Annals of the New York Academy of Sciences 865 (1998) 253-258
46. Van Rampelbergh J., Poloczek P., Francoys I., Delporte C., Winand J., Robberecht P., and Waelbroeck M. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochimica et Biophysica Acta 1357 (1997) 249-255
47. Vanneste G., Robberecht P., and Lefebvre R.A. Inhibitory pathways in the circular muscle of rat jejunum. British Journal of Pharmacology 143 (2004) 107-118
48. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., and Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacological Reviews 52 (2000) 269-324
49. Vertongen P., Devalck C., Sariban E., De Laet M.H., Martelli H., Paraf F., Helardot P., and Robberecht P. Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas. Journal of Cellular Physiology 167 (1996) 36-46
50. Vertongen P., Langlet C., Langer I., Gaspard N., and Robberecht P. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF 8-27- a VPAC1 receptor antagonist - is an inverse agonist on two constitutively active truncated VPAC1 receptors. Peptides 25 (2004) 1943-1949
51. 2+ and cyclic AMP signals. Journal of Clinical Immunology 16 (1996) 21-30
52. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., and Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. Journal of Pharmacology and Experimental Therapeutics 281 (1997) 629-633
53. Yung S.L., Dela C.F., Hamren S., Zhu J., Tsutsumi M., Bloom J.W., Caudle M., Roczniak S., Todd T., Lemoine L., MacDougall M., Shanafelt A.B., and Pan C.Q. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. Journal of Biological Chemistry 278 (2003) 10273-10281